41 results about "Maximum tolerated dose" patented technology

The invention provides a method for obtaining local anesthetics encapsulated in liposomes, such as multivesicular liposomes, with high encapsulation efficiency and slow release in vivo. When the encapsulated anesthetic is administered as a single intracutaneous dose, the duration of anesthesia and half-life of the drug at the local injection site is increased as compared to injection of unencapsulated anesthetic. The maximum tolerated dose of the encapsulated anesthetic is also markedly increased in the liposomal formulation over injection of unencapsulated anesthetic. These results show that the liposomal formulation of local anesthetic is useful for sustained local infiltration and nerve block anesthesia.

There is described a method for increasing the maximal tolerated dose and thus the efficacy of an acetyl choline esterase inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia by decreasing concomitant adverse effects by administration of said AChEI in combination with a non-selective, peripheral anticholinergic agent, whereby an enhanced acetyl choline esterase inhibition in the CNS of said patient is achieved and alleviation of the symptoms of Alzheimer type dementia in said patient is thereby improved to a greater extent. The use of a non-selective, peripheral anticholinergic agent (nsPAChA) for the preparation of a pharmaceutical composition for increasing the maximal tolerated dose and thus the efficacy of an acetyl choline esterase inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia and pharmaceutical compositions comprising a non-selective peripheral anticholinergic agent of formula II as illustrated in the description and an acetylcholine esterase inhibitor are also described.

The invention relates to a method for calculating tolerance dosage of sugar alcohol and function sugar of the human body. Xylitol is taken as an example, and the method comprises the following steps that mice with the volume of 200 g are selected as experimental animal objects, the mice with the volume of 200 g are divided into six experimental groups and one control group, and there are ten numbered mice of each group; the mice of six experimental mice are fed with the xylitol of different dosages in a filling mode every day; the mice of the control group are fed with saccharose in the filling mode; sufficient drinking water and ordinary feed are provided for the experimental mice; the mice are checked every night, and the diarrheal mice are counted; the feeding mode lasts for 14 days; the maximum tolerated dosage of the xylitol of the mice of each group is obtained according to diarrhea conditions of the mice on the last day, intestinal segment slice images of all the mice and the result of content of diamine oxidase; according to a drug dosage reduction formula between the experimental animal and the human, the maximum tolerated dosage of the mouse is converted to obtain the tolerance dosage of the xylitol of the human body. In an animal experiment mode, the range of the tolerance dosage of the sugar alcohol and the function sugar of the human body is obtained more accurately.

The present invention is directed to a method for treating tumors and cancer cells by administering an immunocytokine following radiation treatment. This combination of treatments can stimulate an immune response at irradiated and non-irradiated sites, which is useful in eradicating cancer cells that have spread from the site of the primary tumor. In addition, immunocytokines can be administered at a dose that is less that the maximum tolerated dose, which reduces the side effects associated with immunocytokine therapy.

Methods of treating diseases caused by cell division or that are treated by inhibiting mitosis by administering two doses of an inhibitor of mitosis between the biologically effective dose and the maximum tolerated dose in a dosing cycle that allows for the recovery or subsiding of side effects, wherein the second dose is administered 24 to 48 hours after the first dose.